Verona Pharma (VRNA) Competitors $35.66 +0.29 (+0.82%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VRNA vs. PCVX, CTLT, SRPT, QGEN, RVMD, ITCI, ROIV, ASND, LEGN, and ELANShould you be buying Verona Pharma stock or one of its competitors? The main competitors of Verona Pharma include Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Revolution Medicines (RVMD), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Verona Pharma vs. Vaxcyte Catalent Sarepta Therapeutics Qiagen Revolution Medicines Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Vaxcyte (NASDAQ:PCVX) and Verona Pharma (NASDAQ:VRNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Does the media favor PCVX or VRNA? In the previous week, Vaxcyte had 15 more articles in the media than Verona Pharma. MarketBeat recorded 20 mentions for Vaxcyte and 5 mentions for Verona Pharma. Vaxcyte's average media sentiment score of 0.92 beat Verona Pharma's score of 0.44 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation and earnings, PCVX or VRNA? Verona Pharma has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$4.60-18.88Verona Pharma$460K6,197.09-$54.37M-$1.92-18.57 Do analysts rate PCVX or VRNA? Vaxcyte presently has a consensus target price of $147.50, indicating a potential upside of 69.87%. Verona Pharma has a consensus target price of $43.83, indicating a potential upside of 22.92%. Given Vaxcyte's higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PCVX or VRNA? Verona Pharma received 279 more outperform votes than Vaxcyte when rated by MarketBeat users. Likewise, 80.55% of users gave Verona Pharma an outperform vote while only 74.58% of users gave Vaxcyte an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes4474.58% Underperform Votes1525.42% Verona PharmaOutperform Votes32380.55% Underperform Votes7819.45% Do institutionals and insiders hold more shares of PCVX or VRNA? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is PCVX or VRNA more profitable? Vaxcyte's return on equity of -23.53% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Verona Pharma N/A -79.54%-43.49% Which has more risk & volatility, PCVX or VRNA? Vaxcyte has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. SummaryVaxcyte beats Verona Pharma on 8 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRNA vs. The Competition Export to ExcelMetricVerona PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.85B$6.39B$5.06B$8.66BDividend YieldN/A8.04%5.09%4.06%P/E Ratio-18.5710.80101.8517.37Price / Sales6,197.09245.131,196.8169.07Price / CashN/A53.4940.9136.36Price / Book21.889.306.335.87Net Income-$54.37M$154.14M$119.64M$225.66M7 Day Performance-7.57%-9.49%-5.12%-1.34%1 Month Performance4.79%-7.23%-3.21%1.00%1 Year Performance160.48%30.70%32.52%25.27% Verona Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRNAVerona Pharma2.3777 of 5 stars$35.66+0.8%$43.83+22.9%+160.5%$2.85B$460,000.00-18.5730PCVXVaxcyte3.3295 of 5 stars$86.83-6.3%N/A+73.3%$10.82BN/A-18.88160News CoverageHigh Trading VolumeCTLTCatalent2.8783 of 5 stars$59.10+0.3%N/A+48.7%$10.73B$4.38B-26.1516,900Analyst UpgradeInsider SellingNews CoverageSRPTSarepta Therapeutics4.9455 of 5 stars$104.54-4.2%N/A+26.0%$9.99B$1.24B83.631,314Analyst UpgradeQGENQiagen4.2892 of 5 stars$41.28-1.9%N/A+1.6%$9.42B$1.97B105.855,967Analyst RevisionRVMDRevolution Medicines3.5596 of 5 stars$55.13-3.9%N/A+159.4%$9.27B$11.58M-15.36443ITCIIntra-Cellular Therapies4.5093 of 5 stars$83.42-4.8%N/A+51.6%$8.84B$464.37M-95.88560Insider SellingPositive NewsROIVRoivant Sciences3.4226 of 5 stars$11.20-3.8%N/A+24.2%$8.28B$124.79M1.98860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.06 of 5 stars$126.51+1.8%N/A+35.3%$7.67B$288.08M-13.59640Analyst DowngradeShort Interest ↑News CoverageGap DownHigh Trading VolumeLEGNLegend Biotech1.8575 of 5 stars$38.19-4.3%N/A-39.9%$6.96B$455.99M-40.201,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeELANElanco Animal Health3.5205 of 5 stars$13.98-0.4%N/A+21.5%$6.91B$4.42B34.959,300Short Interest ↑ Related Companies and Tools Related Companies PCVX Alternatives CTLT Alternatives SRPT Alternatives QGEN Alternatives RVMD Alternatives ITCI Alternatives ROIV Alternatives ASND Alternatives LEGN Alternatives ELAN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VRNA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
